Research status of COX-2 and its inhibitor in breast cancer / 国际肿瘤学杂志

ABSTRACT

COX-2 is the rate-limiting enzyme in prostaglandin biosynthesis,which may promote the human tumorigenesis and tumor development through a variety of pathogenic mechanisms.The over expression of COX-2 in breast cancer is significantly correlated with the clinicopathological pammeters and prognosis.COX-2 inhibitors play anti-tumor effects through different mechanisms.Recent studies indicate that COX-2 inhibitors are effective both in breast cancer chemoprevention and treatment of breast cancer combined with cytotoxic drugs and aromatase inaetivators,and therefore may provide a potential new therapy of breast cancer prevention and treatment.